Biotech SF

San Francisco Bay Area biotech stories.

Friday, December 10, 2010

Combo of Genentech's Herceptin, Pertuzumab antibody, chemo shown effective vs. early-stage breast cancer

Posted by Unknown at 5:44 PM
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

TOP STORIES

  • Patients' tales, biotech legends add weight to BayBio awards
    Genentech co-founder Herb Boyer. When two or more biotechs are gathered, you hear the usual phrases, including the old standby, “We'...
  • Medivation nets $10 million as prostate cancer drug moves toward approval
    Medivation Inc. landed $10 million from partner  Astellas Pharma Inc.  after the Food and Drug Administration said the San Francisco drug de...
  • InterWest adds Visiogen founder Zadno to medical devices team
    InterWest Partners added Dr. Reza Zadno as a venture partner to its medical devices team. The Menlo Park-based venture capital firm speciali...
  • Ex-CEO Thomas Okarma departing Geron with $1.3 million, consulting deal, stock
    Former Geron Corp. President and CEO Thomas Okarma could receive up to $1.3 million, including $802,500 in severance pay, according to an ag...
  • Peter Thiel's Breakout Labs funds artificial meat, cell-tracking companies in latest round
    Peter Thiel. A startup using tissue engineering to develop an edible cured meat, and another company whose technology could more easily ...

Some of my favorite stories.

• "The fight of his life" (2007)
Last year Mike Homer helped raise the money for 2,000 medical research computers. Now researchers are using that equipment in an attempt to save his life.

• "For reporter, CJD is more than a story" (2007)
Seven years ago -- nearly to the day -- my mother died of Creutzfeld-Jakob Disease.

• "A son's YouTube plea for Avastin" (2010)
Josh Turnage is your typical teenager, trying to discover what he wants to do in college and with his life. But a 7-minute, 41-second YouTube video he produced about his mother's fight with breast cancer may thrust him into a debate between drug makers and the agency that regulates them.

• "New device could knock out old dialysis technology" (2011)
Shuvo Roy has all the makings for the world's first implantable artificial kidney, thanks to nanotechnology and a web of nationwide collaborations.
All he needs now is $20 million.

Subscribe To

Posts
Atom
Posts
Comments
Atom
Comments

Blog Archive

  • ►  2012 (486)
    • ►  November (18)
    • ►  October (25)
    • ►  September (56)
    • ►  August (56)
    • ►  July (64)
    • ►  June (26)
    • ►  May (40)
    • ►  April (39)
    • ►  March (31)
    • ►  February (74)
    • ►  January (57)
  • ►  2011 (772)
    • ►  December (54)
    • ►  November (40)
    • ►  October (65)
    • ►  September (74)
    • ►  August (48)
    • ►  July (44)
    • ►  June (60)
    • ►  May (70)
    • ►  April (80)
    • ►  March (81)
    • ►  February (77)
    • ►  January (79)
  • ▼  2010 (59)
    • ▼  December (42)
      • Genentech asks for Avastin hearing
      • Biotechs to U.S. attorney general: Save us from Mi...
      • Research Track: UCSF finds new source of immune cells
      • Corcept Cushing's Syndrome drug does well in late-...
      • Gilead kills late-stage IPF drug study
      • Xoma's Xombies: Traders come back to life
      • UC system, BioTime in stem-cell deal
      • Xoma shares rocket on diabetes drug research report
      • Aryx Therapeutics saves money by firing everyone
      • Novartis moving infectious disease unit HQ from Ma...
      • Gilead to buy Palo Alto's Arresto, IPF antibody dr...
      • QB3 looks to spark 'dry kindling' - now if only th...
      • New QB3 entrepreneur-in-residence program linking ...
      • Exelixis cuts to the bone to fund pursuit of cance...
      • InterMune lung drug nears EU approval
      • Gladstone-led HIV prevention study tops Time list
      • Research Track: Looking under the hood of Bay Area...
      • Rescinding Avastin: View from the web
      • FDA rescinds approval of Genentech's Avastin in br...
      • Genentech's Avastin back in front of FDA for breas...
      • Klein to lead California's stem cell agency for up...
      • Merck to make lupus drug for Anthera
      • Vote for me for CIRM chair!
      • SF's Mission Bay coming of age
      • California controller: Suspend process of selectin...
      • PacBio: Targeting disease just a small sequence in...
      • Cytokinetics steps forward with drug to treat ALS ...
      • Pleasanton lab equipment firm QuantaLife raises $17M
      • Combo of Genentech's Herceptin, Pertuzumab antibod...
      • Roche/Genentech plots new pathway into schizophren...
      • InSite eyes FDA approval for two-drug study
      • Study data helps Genomic Health advances prostate ...
      • Out of stealth, Sequenta grabs $13M
      • StemCells wins OK for spinal cord trial
      • Cancer study boosts Genentech's Rituxan
      • Life sciences chip developer Fluidigm files for $8...
      • Klein tabbed by Schwarzenegger to lead CIRM, again
      • GE, UCSF technology IDs aggressive tumors
      • Report: Stem cell agency chair candidate withdraws
      • Hana Biosciences digs in to new Talon name
      • CIRM leaders push Canadian for chairman post
      • Pearl Therapeutics COPD drug passes test
    • ►  November (17)

Search This Blog

TWITTER UPDATES

Dates to Watch

Sept. 5 - PDUFA date for Salix Pharmaceuticals' crofelemer (developed by San Francisco's Napo Pharmaceuticals) for diarrhea in HIV/AIDS patients on antiretroviral therapy.
Oct. 19 - PDUFA date for Impax Pharmaceutical's IPX-066 in Parkinson's
Oct. 23 - PDUFA date for Hyperion Therapeutics' Ravicti in urea cycle disorders.

Calendar

  • "Ushering in the New Medical Device Excise Tax: Will You Be Ready?" 8 a.m. Wednesday, Sept. 5, Abbott Vascular, 3200 Lakeside Drive, Santa Clara. Cost: $20 BayBio members, $40 non-members (through Sept. 3) and $40 members and $75 non-members (after Sept. 3)
Unknown
View my complete profile

My contact information

Ron Leuty
San Francisco Business Times
275 Battery St.,
Suite 940
San Francisco,
CA 94111
415-288-4939 - direct
415-722-2678 - cell
rleuty@
bizjournals.com
http://www.bizjournals.com/sanfrancisco

Follow me on Twitter — rleuty_biotech
— or Facebook or LinkedIn.

For biotech stories from all of ACBJ's 40 business journals — from Boston to Seattle — go to Biotech Day.

Followers

Total Pageviews
Simple theme. Powered by Blogger.